These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34334589)

  • 1. Acromegaly Cases Exhibiting Increased Growth Hormone Levels during Oral Glucose Loading with Preadministration of Dipeptidyl Peptidase-4 Inhibitor.
    Oba-Yamamoto C; Kameda H; Miyoshi H; Sekizaki T; Takase T; Yanagimachi T; Fujita Y; Nomoto H; Cho KY; Nakamura A; Nagai S; Atsumi T
    Intern Med; 2021; 60(15):2375-2383. PubMed ID: 34334589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GIP receptor antagonism eliminates paradoxical growth hormone secretion in some patients with acromegaly.
    Jensen MH; Gasbjerg LS; Skov-Jeppesen K; Jacobsen JCB; Poulsen SS; Zhou C; Jakubauskaite R; Poulsen FR; Bonde C; Albarazi M; Halle B; Christiansen CB; Sanni SJ; Byberg S; Hoe B; Holst JJ; Dela F; Rasmussen AK; Knop FK; Arlien-Søborg MC; Melmed S; Jørgensen JOL; Andersen MS; Hartmann B; Klose MC; Feldt-Rasmussen U; Sparre-Ulrich AH; Rosenkilde MM
    J Clin Endocrinol Metab; 2024 Aug; ():. PubMed ID: 39172542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose.
    Hage M; Janot C; Salenave S; Chanson P; Kamenický P
    Eur J Endocrinol; 2021 May; 184(6):R261-R268. PubMed ID: 33830942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose-dependent insulinotropic polypeptide induced growth hormone secretion in acromegaly.
    Umahara M; Okada S; Ohshima K; Mori M
    Endocr J; 2003 Oct; 50(5):643-50. PubMed ID: 14614222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KDM1A genotyping and expression in 146 sporadic somatotroph pituitary adenomas.
    Chasseloup F; Regazzo D; Tosca L; Proust A; Kuhn E; Hage M; Jublanc C; Mokhtari K; Dalle Nogare M; Avallone S; Ceccato F; Tachdjian G; Salenave S; Young J; Gaillard S; Parker F; Boch AL; Chanson P; Bouligand J; Occhi G; Kamenický P
    Eur J Endocrinol; 2024 Feb; 190(2):173-181. PubMed ID: 38330165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The GIP/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of
    Regazzo D; Losa M; Albiger NM; Terreni MR; Vazza G; Ceccato F; Emanuelli E; Denaro L; Scaroni C; Occhi G
    Eur J Endocrinol; 2017 May; 176(5):543-553. PubMed ID: 28179449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative growth hormone response to thyrotropin-releasing hormone and oral glucose tolerance test in acromegaly: a retrospective evaluation of 50 patients.
    De Marinis L; Mancini A; Bianchi A; Gentilella R; Valle D; Giampietro A; Zuppi P; Anile C; Maira G; Giustina A
    Metabolism; 2002 May; 51(5):616-21. PubMed ID: 11979395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells.
    Occhi G; Losa M; Albiger N; Trivellin G; Regazzo D; Scanarini M; Monteserin-Garcia JL; Fröhlich B; Ferasin S; Terreni MR; Fassina A; Vitiello L; Stalla G; Mantero F; Scaroni C
    J Neuroendocrinol; 2011 Jul; 23(7):641-9. PubMed ID: 21554434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of early postoperative random growth hormone levels and nadir growth hormone levels after oral glucose tolerance testing in acromegaly.
    Rotermund R; Burkhardt T; Rohani Z; Jung R; Aberle J; Flitsch J
    Growth Horm IGF Res; 2018 Aug; 41():64-70. PubMed ID: 29555234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1.
    Parfitt VJ; Flanagan D; Wood P; Leatherdale BA
    Clin Endocrinol (Oxf); 1998 Nov; 49(5):647-52. PubMed ID: 10197081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone responses to oral glucose and intravenous thyrotropin-releasing hormone in acromegalic patients treated by slow-release lanreotide.
    Díez JJ; Iglesias P; Gómez-Pan A
    J Endocrinol Invest; 2001 May; 24(5):303-9. PubMed ID: 11407648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
    Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
    J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.
    Plöckinger U; Holst JJ; Messerschmidt D; Hopfenmüller W; Quabbe HJ
    Eur J Endocrinol; 1999 Jun; 140(6):538-44. PubMed ID: 10377503
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of tumor characteristics and pre- and postoperative hormone levels on hormonal remission following endoscopic transsphenoidal surgery in patients with acromegaly.
    Cardinal T; Rutkowski MJ; Micko A; Shiroishi M; Jason Liu CS; Wrobel B; Carmichael J; Zada G
    Neurosurg Focus; 2020 Jun; 48(6):E10. PubMed ID: 32480366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects.
    Yanagimachi T; Fujita Y; Takeda Y; Honjo J; Sakagami H; Kitsunai H; Takiyama Y; Abiko A; Makino Y; Kieffer TJ; Haneda M
    Mol Metab; 2017 Feb; 6(2):226-231. PubMed ID: 28180064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-Negative Somatotropinomas.
    Hage M; Chaligné R; Viengchareun S; Villa C; Salenave S; Bouligand J; Letouzé E; Tosca L; Rouquette A; Tachdjian G; Parker F; Lombès M; Lacroix A; Gaillard S; Chanson P; Kamenický P
    J Clin Endocrinol Metab; 2019 May; 104(5):1777-1787. PubMed ID: 30376114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paradoxical GH increase during oral glucose load may predict overall remission in acromegalic patients.
    Düğer H; Bostan H; Deryol HY; İmga NN; Uçan B; Çalapkulu M; Hepşen S; Akhanlı P; Gül Ü; Sencar ME; Çakal E; Özdemir Ş; Kızılgül M
    Growth Horm IGF Res; 2022 Dec; 67():101501. PubMed ID: 36166917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly.
    Carmichael JD; Bonert VS; Mirocha JM; Melmed S
    J Clin Endocrinol Metab; 2009 Feb; 94(2):523-7. PubMed ID: 19033371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting long-term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly.
    Kim EH; Oh MC; Lee EJ; Kim SH
    Neurosurgery; 2012 May; 70(5):1106-13; discussion 1113. PubMed ID: 22067418
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of disease activity in treated acromegalic patients using a sensitive GH assay: should we achieve strict normal GH levels for a biochemical cure?
    Costa AC; Rossi A; Martinelli CE; Machado HR; Moreira AC
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3142-7. PubMed ID: 12107214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.